[1]
|
C. C. Sun, D. C. Bodurka, C. B. Weaver, et al., “Rankings and Symptom Assessments of Side Effects from Chemotherapy: Insights from Experienced Patients with Ovarian Cancer,” Supportive Care in Cancer, Vol. 13, No. 4, 2005, pp. 219-227. doi:10.1007/s00520-004-0710-6
|
[2]
|
A. Fabi, M. Barduagni, S. Lauro, et al., “Is Delayed Chemotherapy-Induced Emesis Well Managed in Oncological clinical Practice? An Observational Study,” Supportive Care in Cancer, Vol. 11, No. 3, 2003, pp. 156-161.
doi:10.1007/s00520-002-0427-3
|
[3]
|
S. Grunberg, R. Deuson, P. Mavros, et al., “Incidence of Chemotherapy-Induced Nausea and Emesis after Modern Antiemetics: Perception versus Reality,” Cancer, Vol. 100, No. 10, 2004, pp. 2261-2268.
doi:10.1002/cncr.20230
|
[4]
|
K. G. Reddy, R. J. Gralla and P. J. Hesketh, “Novel Neurokinin-1 Antagonists as Antiemetics for the Treatment of Chemotherapy-Induced Emesis,” Supportive Cancer Therapy, Vol. 3, No. 3, 2006, pp. 140-142.
doi:10.3816/SCT.2006.n.011
|
[5]
|
M. Kris, P. Hesketh, M. Somerfield, et al., “American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,” Journal of Clinical Oncology, Vol. 24, No. 18, 2006, pp. 2932-2947.
doi:10.1200/JCO.2006.06.9591
|
[6]
|
National Comprehensive Cancer Network, “NCCN Clinical Practice Guidelines in Oncology—Antiemesis (Version I.2012),” 2011.
http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
|
[7]
|
R. J. Gralla, F. Roila, M. Tonato and J. Herrstedt, “MASCC/ ESMO Antiemetic Guideline 2011,” 2011.
http://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2011.pdf
|
[8]
|
R. Twycross and A. Wilcock, “Nausea and Vomiting,” Symptom Management in Advanced Cancer, Radcliffe Medical Press, Oxford, 2002, pp. 104-110.
|
[9]
|
S.-C. J. Yeung, C. P. Escalante and R. F. Gagel, “Medical Care of Cancer Patients,” People’s Medical Publishing House, USA, 2009.
|
[10]
|
M. P. Curran and D. M. Robinson, “Aprepitant: A Review of Its Use in the Prevention of Nausea and Vomiting,” Drugs, Vol. 69, No. 13, 2009, pp. 1853-1878.
doi:10.2165/11203680-000000000-00000
|
[11]
|
J. Herrstedt, W. Arpornwirat, A. Shaharyar, et al., “Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy,” Journal of Clinical Oncology, Vol. 27, No. 32, 2009, pp. 5363-5369. doi:10.1200/JCO.2009.21.8511
|
[12]
|
B. L. Rapoport, K. Jordan, J. A. Boice, et al., “Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with a Broad Range of Moderately Emetogenic Chemotherapies and Tumor Types: A Randomized, Double-Blind Study,” Supportive Care in Cancer, Vol. 18, No. 4, 2010, pp. 423-431.
doi:10.1007/s00520-009-0680-9
|
[13]
|
Health Promotion Board National Registry of Diseases Office, “Singapore Cancer Registry Interim Report: Trends in Cancer Incidence in Singapore 2004-2008,” 2010.
http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/Cancer_Trends_Report0408_web_v2.pdf
|
[14]
|
B. Fisher, S. Anderson, D. L. Wickerham, et al., “Increased Intensification and Total Dose of Cyclophosphamide in a Doxorubicin-Cyclophosphamide Regimen for the Treatment of Primary Breast Cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22,” Journal of Clinical Oncology, Vol. 15, No. 5, 1997, pp. 1858-1869.
|
[15]
|
B. Fisher, A. M. Brown, N. V. Dimitrov, et al., “Two Months of Doxorubicin-Cyclophosphamide with and without Interval Reinduction Therapy Compared with 6 Months of Cyclophosphamide, Methotrexate and Fluorouracil in Positive-Node Breast Cancer Patients with Tamoxifen-Nonresponsive Tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15,” Journal of Clinical Oncology, Vol. 8, No. 9, 1990, pp. 1483-1496.
|
[16]
|
J. M. Nabholtz, C. Falkson, D. Campos, et al., “Docetaxel and Doxorubicin Compared with Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic breast Cancer: Results of a Randomized, Multicenter, Phase III Trial,” Journal of Clinical Oncology, Vol. 21, No. 6, 2003, pp. 968-975. doi:10.1200/JCO.2003.04.040
|
[17]
|
T. Grote, J. Hajdenberg, A. Cartmell, et al., “Combination Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Palonosetron, Dexamethasone and Aprepitant,” Journal of Supportive Oncology, Vol. 4, No. 8, 2006, pp. 403-408.
|
[18]
|
W. Arpornwirat, I. Albert, V. L. Hansen, et al., “Phase 2 Trial Results with the Novel Neurokinin-1 Receptor Antagonist Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy,” Cancer, Vol. 115, No. 24, 2009, pp. 5807-5816.
doi:10.1002/cncr.24630
|
[19]
|
J. Herrstedt, H. B. Muss, D. G. Warr, et al., “Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Emesis over Multiple Cycles of Moderately Emetogenic Chemotherapy,” Cancer, Vol. 104, No. 7, 2005, pp. 1548-1555. doi:10.1002/cncr.21343
|
[20]
|
P. J. Hesketh, J. Younger, P. Sanz-Altamira, et al., “Aprepitant as Salvage Antiemetic Therapy in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide,” Supportive Care in Cancer, Vol. 17, No. 8, 2009, pp. 1065-1070. doi:10.1007/s00520-008-0545-7
|
[21]
|
D. G. Warr, P. J. Hesketh, R. J. Gralla, et al., “Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer after Moderately Emetogenic Chemotherapy,” Journal of Clinical Oncology, Vol. 23, No. 12, 2005, pp. 2822-2830. doi:10.1200/JCO.2005.09.050
|
[22]
|
W. Yeo, F. K. F. Mo, J. J. S. Suen, et al., “A randomized study of Aprepitant, Ondansetron and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients Receving Moderately Emetogenic Chemotherapy,” Breast Cancer Research and Treatment, Vol. 113, No. 3, 2009, pp. 529-535.
doi:10.1007/s10549-008-9957-9
|
[23]
|
M. S. Aapro and C. M. Walko, “Aprepitant: Drug-Drug Interactions in Perspective,” Annals of Oncology, Vol. 21, No. 12, 2010, pp. 2316-2323.
doi:10.1093/annonc/mdq149
|
[24]
|
National Cancer Institute, “Common Terminology Criteria for Adverse Events v3.0 (CTCAE),” 2006.
http://www.eortc.be/services/doc/ctc/ctcaev3.pdf
|
[25]
|
R. Gralla, M. Lichinitser, S. Van der Vegt, et al., “Palonosetron Improved Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron with Ondansetron,” Annals of Oncology, Vol. 14, No. 10, 2003, pp. 1570-1577. doi:10.1093/annonc/mdg417
|
[26]
|
P. J. Hesketh, M. Aapro, J. C. Street and A. D. Carides, “Evaluation of Risk Factors Predictive of Nausea and Vomiting with Current Standard-of-Care Antiemetic Treatment: Analysis of Two Phase III Trials of Aprepitant in Patients Receiving Cisplatin-Based Chemotherapy,” Supportive Care in Cancer, Vol. 18, No. 9, 2010, pp. 1171-1177. doi:10.1007/s00520-009-0737-9
|
[27]
|
D. G. Warr, J. C. Street and A. D. Carides, “Evaluation of Risk Factors Predictive of Nausea and Vomiting with Current Standard-of-Care Antiemetic Treatment: Analysis of Phase 3 Trial of Aprepitant in Patients Receiving Adriamycin-Cyclophosphamide-Based Chemotherapy,” Supportive Care in Cancer, Vol. 19, No. 6, 2011, pp. 807-813. doi:10.1007/s00520-010-0899-5
|
[28]
|
V. Shih, S. W. Hee and A. Chan, “Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide,” Annals of Pharmacotherapy, Vol. 43, No. 3, 2009, pp. 444-452. doi:10.1345/aph.1L437
|
[29]
|
J. K. Lamba, Y. S. Lin, E. G. Schuetz and K. E. Thummel, “Genetic Contribution to Variable Human CYP3A-Mediated Metabolism,” Advanced Drug Delivery Reviews, Vol. 54, No. 10, 2002, pp. 1271-1294.
doi:10.1016/S0169-409X(02)00066-2
|
[30]
|
R. I. Sanchez, R. W. Wang, D. J. Newton, et al., “Cytochrome P450 3A4 Is the Major Enzyme Involved in the Metabolism of the Substance P Receptor Antagonist Aprepitant,” Drug Metabolism and Disposition, Vol. 32, No. 11, 2004, pp. 1287-1292.
doi:10.1124/dmd.104.000216
|
[31]
|
J. F. Solus, B. J. Arietta, J. R. Harris, et al., “Genetic Variation in Eleven Phase I Drug Metabolism Genes in an Ethnically Diverse Population,” Pharmacogenomics, Vol. 5, No. 7, 2004, pp. 895-931.
doi:10.1517/14622416.5.7.895
|
[32]
|
GlaxoSmithKline, “Withdrawal of Marketing Authorisation Application for Zunrisa (as Casopitant Mesilate), 50 mg and 150 mg film coated tablets—EMEA/H/C/1040,” 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500060224.pdf
|
[33]
|
P. J. Hesketh and P. Sanz-Altamira, “Aprepitant, Dexamethasone, and Palonosetron in the Prevention of Doxorubicin/Cyclophosphamide-Induced Nausea and Vomiting,” Supportive Care in Cancer, epub ahead of print, 2011. doi:10.1007/s00520-011-1312-8
|
[34]
|
E. Basch, A. A. Prestrud, P. J. Hesketh, et al., “Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,” Journal of Clinical Oncology, Vol. 29, No. 31, 2011, pp. 4189-4198.
doi:10.1200/JCO.2010.34.4614
|
[35]
|
M. Majem, M. E. Moreno, N. Calvo, et al., “Perception of Healthcare Providers versus Patient Reported Incidence of Chemotherapy-Induced Nausea and Vomiting after the Addition of NK-1 Receptor Antagonists,” Supportive Care in Cancer, Vol. 19, No. 12, 2011, pp. 1983-1990.
doi:10.1007/s00520-010-1042-3
|
[36]
|
S. M. Grunberg, D. Warr, R. J. Gralla, et al., “Evaluation of New Antiemetic Agents and Definition of Antineoplastic Agent Emetogenicity—State of the Art,” Supportive Care in Cancer, Vol. 19 No. Supplement 1, 2011, pp. S43-S47. doi:10.1007/s00520-010-1003-x
|
[37]
|
R. M. Navari, S. E. Gray and A. C. Kerr, “Olanzapine versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial,” Journal of Supportive Oncology, Vol. 9, No. 5, 2011, pp. 188-195. doi:10.1016/j.suponc.2011.05.002
|
[38]
|
D. A. Perwitasari, H. Gelderblom, J. Atthobari, et al., “Anti-emetic Drugs in Oncology: Pharmacology and Individualization by Pharmacogenetics,” International Journal of Clinical Pharmacy, Vol. 33, No. 1, 2011, pp. 33-43.
doi:10.1007/s11096-010-9454-1
|
[39]
|
T. Takahashi, Y. Nakamura, A. Tsuya, et al., “Pharmacokinetics of Aprepitant and Dexamethasone after Administration of Chemotherapeutic Agents and Effects of Plasma Substance P Concentration on Chemotherapy-Induced Nausea and Vomiting in Japanese Cancer Patients,” Cancer Chemotherapy and Pharmacology, Vol. 68, No. 3, 2011, pp. 653-659. doi:10.1007/s00280-010-1519-2
|
[40]
|
T. J. Gan, J. Gu, N. Singla, et al., “Rolapitant for the Prevention of Postoperative Nausea and Vomiting: A Prospective, Double-Blinded, Placebo-Controlled Randomized trial,” Anesthesia and Analgesia, Vol. 112, No. 4, 2011, pp. 804-812. doi:10.1213/ANE.0b013e31820886c3
|
[41]
|
K. Dhanachandra Singh, M. Karthikeyan, P. Kirubakaran and S. Nagamani, “Pharmacophore Filtering and 3D-QSAR in the Discovery of New JAK2 Inhibitors,” Journal of Molecular Graphics and Modelling, Vol. 30, 2011, pp. 186-197. doi:10.1016/j.jmgm.2011.07.004
|
[42]
|
A. Weaver, A. M. Young, J. Rowntree, et al., “Application of Mobile Phone Technology for Managing Chemo- therapy-Associated Side-Effects,” Annals of Oncology, Vol. 18, No. 11, 2007, pp. 1887-1892.
doi:10.1093/annonc/mdm354
|
[43]
|
K. Y.-L. Yap, X. R. Yak, V. Shih, W. K. Chui and A. Chan, “Application of Unsupervised Learning in Clinical Oncology Practice—Exploring Anxiety Characteristics in Chemotherapy-Induced Nausea and Vomiting through Principal Variables,” Journal of Computing, Vol. 2, No. 7, 2010, pp. 163-171.
|